Flexion Adds $20M in Series B on Newly Focused OA Pipeline
By Jennifer Boggs
Monday, December 3, 2012
Flexion Therapeutics Inc. is proving that, in drug development, it pays to stay flexible. The company disclosed a $20 million Series B financing led by new investor Novo Ventures, joined by existing investors 5AM Ventures, Pfizer Venture Investments, Sofinnova Partners and Versant Ventures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.